Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information communication from Merck Sharp & Dohme B.V on Keytruda (pembrolizumab): Restriction of indication for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy.
Important Safety Information - Keytruda (pembrolizumab)